Compare Mesoblast Limited (MESO) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs PayPal Holdings, Inc. — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while PayPal Holdings, Inc. trades at $55.07 (market cap $47.01B). The key difference: PayPal Holdings, Inc. is far larger — about 26× Mesoblast Limited's market cap, and PayPal Holdings, Inc. pays a 1.02% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and PayPal Holdings, Inc. for 106 Days on average.
| MESO | PYPL | |
|---|---|---|
Market Cap | $1.81B | $47.01B |
Volume | 240,620 | 10,493,459 |
Sector | Health | Financials |
52-Week High | $20.96 | $75.75 |
52-Week Low | $13.19 | $39.08 |
Typical Hold Time | 14 Days | 106 Days |
Enterprise Value | $1.89B | $49.15B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
PayPal (PYPL) trades at $54.95, up 0.62% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $56.47. The stock shows strong profitability with a net income margin of 14.36% and ROE of 24.5%, supported by recent earnings beats in Q1 and Q2 2026. A new partnership with Meta's AI agent for checkout services, announced on September 22, 2026, provides a potential growth catalyst amid competitive pressures in digital payments.
PYPL presents a value opportunity with a low P/E of 10.39 and solid cash flow, but faces risks from slowing branded checkout growth and intense fintech competition. The stock's upside hinges on successful execution of Venmo expansion and cost-cutting initiatives under new CEO Enrique Lores, with investor sentiment cautiously optimistic given the 35.71% buy rating from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
